drugset / Trial / NCT05556824
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
Phase 2
Active not recruiting
247 enrolled
Microbiome Health Sciences
VBHRC Virginia Catalyst · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn-free days in subjects with GERD-related heartburn symptoms.
Timeline
- Start
- 2023-03-03
- Primary completion
- 2026-05
- Completion
- 2026-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MHS-1031 | Other / unclassified | 1 g | — |